Search

Your search keyword '"McAlpine, Jessica N."' showing total 21 results
Start Over Author "McAlpine, Jessica N." Publisher wiley
21 results on '"McAlpine, Jessica N."'

5. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis

Author

McAlpine, Jessica N., primary, Chiu, Derek S., additional, Nout, Remi A., additional, Church, David N., additional, Schmidt, Pascal, additional, Lam, Stephanie, additional, Leung, Samuel, additional, Bellone, Stefania, additional, Wong, Adele, additional, Brucker, Sara Y., additional, Lee, Cheng Han, additional, Clarke, Blaise A., additional, Huntsman, David G., additional, Bernardini, Marcus Q., additional, Ngeow, Joanne, additional, Santin, Alessandro D., additional, Goodfellow, Paul, additional, Levine, Douglas A., additional, Köbel, Martin, additional, Kommoss, Stefan, additional, Bosse, Tjalling, additional, Gilks, C. Blake, additional, and Talhouk, Aline, additional

Published
2021
Full Text
View/download PDF

6. Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours

Author

Cochrane, Dawn R, primary, Campbell, Kieran R, additional, Greening, Kendall, additional, Ho, Germain C, additional, Hopkins, James, additional, Bui, Minh, additional, Douglas, J Maxwell, additional, Sharlandjieva, Vassilena, additional, Munzur, Aslı D, additional, Lai, Daniel, additional, DeGrood, Maya, additional, Gibbard, Evan W, additional, Leung, Samuel, additional, Boyd, Niki, additional, Cheng, Angela S, additional, Chow, Christine, additional, Lim, Jamie LP, additional, Farnell, David A, additional, Kommoss, Stefan, additional, Kommoss, Friedrich, additional, Roth, Andrew, additional, Hoang, Lien, additional, McAlpine, Jessica N, additional, Shah, Sohrab P, additional, and Huntsman, David G, additional

Published
2020
Full Text
View/download PDF

7. Interpretation of somatic POLE mutations in endometrial carcinoma

Author

León‐Castillo, Alicia, primary, Britton, Heidi, additional, McConechy, Melissa K, additional, McAlpine, Jessica N, additional, Nout, Remi, additional, Kommoss, Stefan, additional, Brucker, Sara Y, additional, Carlson, Joseph W, additional, Epstein, Elisabeth, additional, Rau, Tilman T, additional, Bosse, Tjalling, additional, Church, David N, additional, and Gilks, C Blake, additional

Published
2020
Full Text
View/download PDF

8. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas

Author

León‐Castillo, Alicia, primary, Gilvazquez, Ester, additional, Nout, Remi, additional, Smit, Vincent THBM, additional, McAlpine, Jessica N, additional, McConechy, Melissa, additional, Kommoss, Stefan, additional, Brucker, Sara Y, additional, Carlson, Joseph W, additional, Epstein, Elisabeth, additional, Rau, Tilman T, additional, Soslow, Robert A, additional, Ganesan, Raji, additional, Matias‐Guiu, Xavier, additional, Oliva, Esther, additional, Harrison, Beth T, additional, Church, David N, additional, Gilks, C Blake, additional, and Bosse, Tjalling, additional

Published
2020
Full Text
View/download PDF

10. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification

Author

Karnezis, Anthony N, primary, Leung, Samuel, additional, Magrill, Jamie, additional, McConechy, Melissa K, additional, Yang, Winnie, additional, Chow, Christine, additional, Kobel, Martin, additional, Lee, Cheng-Han, additional, Huntsman, David G, additional, Talhouk, Aline, additional, Kommoss, Friederich, additional, Gilks, C Blake, additional, and McAlpine, Jessica N, additional

Published
2017
Full Text
View/download PDF

11. Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?

Author

Cochrane, Dawn R, primary, Tessier-Cloutier, Basile, additional, Lawrence, Katherine M, additional, Nazeran, Tayyebeh, additional, Karnezis, Anthony N, additional, Salamanca, Clara, additional, Cheng, Angela S, additional, McAlpine, Jessica N, additional, Hoang, Lien N, additional, Gilks, C Blake, additional, and Huntsman, David G, additional

Published
2017
Full Text
View/download PDF

13. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer

Author

Talhouk, Aline, primary, McConechy, Melissa K., additional, Leung, Samuel, additional, Yang, Winnie, additional, Lum, Amy, additional, Senz, Janine, additional, Boyd, Niki, additional, Pike, Judith, additional, Anglesio, Michael, additional, Kwon, Janice S., additional, Karnezis, Anthony N., additional, Huntsman, David G., additional, Gilks, C. Blake, additional, and McAlpine, Jessica N., additional

Published
2017
Full Text
View/download PDF

16. In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas

Author

McConechy, Melissa K, primary, Hoang, Lien N, additional, Chui, Michael Herman, additional, Senz, Janine, additional, Yang, Winnie, additional, Rozenberg, Nirit, additional, Mackenzie, Robertson, additional, McAlpine, Jessica N, additional, Huntsman, David G, additional, Clarke, Blaise A, additional, Gilks, Cyril Blake, additional, and Lee, Cheng‐Han, additional

Published
2015
Full Text
View/download PDF

17. Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling

Author

Bashashati, Ali, primary, Ha, Gavin, additional, Tone, Alicia, additional, Ding, Jiarui, additional, Prentice, Leah M, additional, Roth, Andrew, additional, Rosner, Jamie, additional, Shumansky, Karey, additional, Kalloger, Steve, additional, Senz, Janine, additional, Yang, Winnie, additional, McConechy, Melissa, additional, Melnyk, Nataliya, additional, Anglesio, Michael, additional, Luk, Margaret TY, additional, Tse, Kane, additional, Zeng, Thomas, additional, Moore, Richard, additional, Zhao, Yongjun, additional, Marra, Marco A, additional, Gilks, Blake, additional, Yip, Stephen, additional, Huntsman, David G, additional, McAlpine, Jessica N, additional, and Shah, Sohrab P, additional

Published
2013
Full Text
View/download PDF

18. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas

Author

Anglesio, Michael S, primary, Kommoss, Stefan, additional, Tolcher, Mary C, additional, Clarke, Blaise, additional, Galletta, Laura, additional, Porter, Henry, additional, Damaraju, Sambasivarao, additional, Fereday, Sian, additional, Winterhoff, Boris J, additional, Kalloger, Steve E, additional, Senz, Janine, additional, Yang, Winnie, additional, Steed, Helen, additional, Allo, Ghassan, additional, Ferguson, Sarah, additional, Shaw, Patricia, additional, Teoman, Attila, additional, Garcia, Joaquin J, additional, Schoolmeester, John K, additional, Bakkum‐Gamez, Jamie, additional, Tinker, Anna V, additional, Bowtell, David D, additional, Huntsman, David G, additional, Gilks, C Blake, additional, and McAlpine, Jessica N, additional

Published
2012
Full Text
View/download PDF

19. Use of mutation profiles to refine the classification of endometrial carcinomas

Author

McConechy, Melissa K, primary, Ding, Jiarui, additional, Cheang, Maggie CU, additional, Wiegand, Kimberly C, additional, Senz, Janine, additional, Tone, Alicia A, additional, Yang, Winnie, additional, Prentice, Leah M, additional, Tse, Kane, additional, Zeng, Thomas, additional, McDonald, Helen, additional, Schmidt, Amy P, additional, Mutch, David G, additional, McAlpine, Jessica N, additional, Hirst, Martin, additional, Shah, Sohrab P, additional, Lee, Cheng-Han, additional, Goodfellow, Paul J, additional, Gilks, C Blake, additional, and Huntsman, David G, additional

Published
2012
Full Text
View/download PDF

20. Clinicopathological and molecular characterisation of 'multiple classifier' endometrial carcinomas

Author

León-Castillo, Alicia, Gilvazquez, Ester, Nout, Remi, Smit, Vincent T H B M, McAlpine, Jessica N, McConechy, Melissa, Kommoss, Stefan, Brucker, Sara Y, Carlson, Joseph W, Epstein, Elisabeth, Rau, Tilman, Soslow, Robert A, Ganesan, Raji, Matias-Guiu, Xavier, Oliva, Esther, Harrison, Beth T, Church, David N, Gilks, C Blake, and Bosse, Tjalling

Subjects
570 Life sciences, biology, 610 Medicine & health, 3. Good health
Abstract

Endometrial carcinoma (EC) molecular classification based on four molecular subclasses identified in The Cancer Genome Atlas (TCGA) has gained relevance in recent years due to its prognostic utility and potential to predict benefit from adjuvant treatment. While most ECs can be classified based on a single-classifier (POLE exonuclease domain mutations - POLEmut, MMR deficiency - MMRd, p53 abnormal - p53abn), a small but clinically relevant group of tumours harbour more than one molecular classifying feature and are referred to as "Multiple classifier" ECs. We aimed to describe the clinicopathological and molecular features of multiple classifier ECs with abnormal p53 (p53abn). Within a cohort of 3518 molecularly profiled EC, 107 (3%) tumours displayed p53abn in addition to another classifier(s), including 64 with MMRd (MMRd-p53abn), 31 with POLEmut (POLEmut-p53abn) and 12 with all three aberrations (MMRd-POLEmut-p53abn). MMRd-p53abn EC and POLEmut-p53abn EC were mostly grade 3 endometrioid EC, early stage, and frequently showed morphologic features characteristic of MMRd or POLEmut EC.18/28 (60%) MMRd-p53abn EC and 7/15 (46.7%) POLEmut-p53abn EC showed subclonal p53 overexpression, suggesting TP53 mutation was a secondary event acquired during tumour progression. Hierarchical clustering of TCGA ECs by single nucleotide variant (SNV) type and somatic copy number alterations (SCNAs) revealed that MMRd-p53abn tumours mostly clustered with single-classifier MMRd tumours (20/23) rather than single-classifier p53abn tumours (3/23), while POLEmut-p53abn tumours mostly clustered with single-classifier POLEmut tumours (12/13) and seldom with single-classifier p53abn tumours (1/13) (both p≤0.001 Chi-square test). Finally, the clinical outcome of patients with MMRd-p53abn and POLEmut-p53abn EC (stage I 5-year recurrence free survival (RFS) of 92.2% and 94.1% respectively) was significantly different from single-classifier p53abn EC (stage I RFS 70.8%, p=0.024 and p= 0.050 respectively). Our results support the classification of MMRd-p53abn EC as MMRd and POLEmut-p53abn EC as POLEmut. This article is protected by copyright. All rights reserved.

21. Challenges in implementation of molecular classification in early stage endometrial cancer-An NRG Oncology cooperative group mixed-methods study.

Author

Wilson EM, Huang R, Jones KD, Hagemann IS, Temkin SM, McAlpine JN, Powell MA, Kepper MM, and Hagemann AR

Abstract

Background: Professional guidelines recommend molecular profiling for mismatch repair (MMR), p53, and polymerase epsilon (POLE) status in endometrial cancer (EC). However, adoption in the United States has not been documented, and barriers to the implementation of testing have not been described., Methods: In this mixed-methods study, implementation science frameworks were used to develop a quantitative survey. Gynecologic oncologists, medical oncologists, radiation oncologists, and pathologists affiliated with NRG Oncology programs were contacted through snowball sampling and were surveyed during 2022-2023. A subset of respondents was interviewed. Statistical and thematic analyses were performed., Results: At least 403 NRG Oncology-affiliated providers were contacted for the survey, and 107 (26.6%) responded. Greater than 90% of respondents perceived POLE, MMR, and p53 status as important for clinical care. MMR and p53 tests were perceived as easy to obtain, but only 24.2% of respondents reported that POLE testing was moderately or very easy to obtain. Respondents from academic sites reported better access to molecular classification and perceived greater importance of molecular classification compared with respondents from community sites. In thematic analysis of 13 qualitative interviews, cost concerns were reported as large barriers to testing. Interviewees reported a desire for prospective data to guide treatment selection based on classification results., Conclusions: Although integrating molecular classification into standard pathologic reporting is recommended, and clinicians perceive molecular profiling in early stage EC as important, survey respondents noted significant implementation barriers. Implementation challenges that differ between community oncology and academic practice settings were identified. Strategies to improve equitable access to molecular classification of early stage EC are needed., (© 2024 American Cancer Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results